Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Down 55.8% in July

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 154,671 shares, a decrease of 55.8% from the July 15th total of 349,646 shares. Approximately 1.0% of the company’s stock are short sold. Based on an average daily trading volume, of 769,462 shares, the days-to-cover ratio is presently 0.2 days.

Azitra Trading Down 3.1%

NYSEAMERICAN:AZTR traded down $0.00 during mid-day trading on Monday, hitting $0.14. 219,957 shares of the company’s stock were exchanged, compared to its average volume of 9,843,673. Azitra has a one year low of $0.10 and a one year high of $1.40. The business has a fifty day moving average price of $0.16 and a 200 day moving average price of $0.19.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05). As a group, analysts forecast that Azitra will post -0.25 EPS for the current fiscal year.

Azitra Company Profile

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.